Kinarus Therapeutics Alternatives & Competitors
12 companies similar to Kinarus Therapeutics — Kinarus Therapeutics is a clinical-stage company developing therapies for viral,...
Companies similar to Kinarus Therapeutics
Molecure
Fate can be altered.
InterCure
Harness the power of respiratory-based treatment for hypertension and heart failure with i...
X4 Pharmaceuticals
Enabling a better future for people with rare immune disorders
Antios Therapeutics
Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing th...
Rival Readout
Competing with Kinarus Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
MethylGene
Harnessing Innovation to Develop Next-Generation Cancer Therapies
GEn1E Lifesciences Inc.
Clinical-stage, Phase 2 company accelerating novel Precision Therapies for I&I and Rare Di...
Lineage Cell Therapeutics
A clinical-stage biotechnology company developing novel cell therapies for unmet medical n...
Phenomix
A pioneering biotech company dedicated to developing groundbreaking therapies for diabetes...
Curis
Working relentlessly to develop innovative and differentiated therapeutics that improve th...
Kodiak Sciences
We are a clinical stage biopharma company bringing new science to prevent and treat high p...
Edesa Biotech, Inc.
Clinical stage treatments for inflammatory and immune-related diseases (Nasdaq: EDSA)
Bionure
Clinical stage biotech developing new drugs for CNS diseases.
About Kinarus Therapeutics
Kinarus Therapeutics is a clinical-stage pharmaceutical company based in Switzerland. Established in 2017, the company is dedicated to developing innovative treatments for viral, respiratory, and ophthalmic diseases. Their flagship drug candidate is an oral combination of a P38 mitogen-activated protein kinase (p38 MAP...
Clinical-stage Pharmaceutical Company, Drug Development, Viral Diseases, Respiratory Diseases, Ophthalmic Diseases, P38 MAPK Inhibitor, Covid-19 Treatment, Phase 2 Clinical Trial, Age-Related Macular Degeneration, VEGF Inhibitors, Regulatory Approval, Patient-focused Treatments, Switzerland-based Company, Roche Collaboration, Hospitalized Patients
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Kinarus Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Kinarus Therapeutics on 12 Sep 2024. The 11 companies listed here were last checked between 19 Jun 2024 and 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.